Literature DB >> 9712183

Variations of rat brain calmodulin content in dark and light phases: effect of pentylenetetrazol-induced kindling.

M Asai1, G Benítez-King.   

Abstract

Calmodulin (CaM) through activation of CaM-kinase II may be involved in the molecular mechanisms underlying the epileptogenic processes. Some evidence suggests that kindling responses change across the day-night cycle. In order to test if kindling stimulation modifies CaM content, we measured CaM concentrations in amygdala, hippocampus and hypothalamus obtained from control and kindled rats during light and darkness. Male Wistar rats (250-300 g), were injected i.p. with Pentylenetetrazol (PTZ) (35 mg/kg/24 h). Once chemical kindling was established, rats were sacrificed by decapitation at 10:30 a.m. and 01:30 a.m. The brains were obtained, and the amygdala, hippocampus and hypothalamus dissected. CaM content was measured in the cytosol and membrane fractions by radioimmunoassay. We found a significant increase in CaM content in cytosol and membrane fractions of both control and kindled rats during the dark phase. No significant differences in CaM concentrations were observed between control and experimental rats, whether during the light or the dark phase. The data suggest a well defined photoperiodic variation in CaM concentrations in limbic structures, despite the neuronal excitability produced by kindling. In addition, the observed CaM increases during the dark time may be related to a protective mechanism against enhanced sensitivity to seizures observed during the night.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712183     DOI: 10.1023/a:1020717732261

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

1.  Kindling induced changes in calmodulin kinase II immunoreactivity.

Authors:  J M Bronstein; D B Farber; P E Micevych; R Lasher; C G Wasterlain
Journal:  Brain Res       Date:  1990-07-30       Impact factor: 3.252

2.  Effect of anticonvulsants on seizures developing in the course of daily administration of pentetrazol to rats.

Authors:  T Ito; M Hori; K Yoshida; M Shimizu
Journal:  Eur J Pharmacol       Date:  1977-09-15       Impact factor: 4.432

Review 3.  The molecular basis of kindling.

Authors:  I Mody
Journal:  Brain Pathol       Date:  1993-10       Impact factor: 6.508

Review 4.  Physiological implications of the presence, distribution, and regulation of calmodulin in eukaryotic cells.

Authors:  A R Means; J S Tash; J G Chafouleas
Journal:  Physiol Rev       Date:  1982-01       Impact factor: 37.312

5.  The anticonvulsant properties of melatonin on kindled seizures in rats.

Authors:  T E Albertson; S L Peterson; L G Stark; M L Lakin; W D Winters
Journal:  Neuropharmacology       Date:  1981-01       Impact factor: 5.250

6.  Development of kindled seizures and circadian rhythms.

Authors:  F G Freeman
Journal:  Behav Neural Biol       Date:  1980-10

7.  A permanent change in brain function resulting from daily electrical stimulation.

Authors:  G V Goddard; D C McIntyre; C K Leech
Journal:  Exp Neurol       Date:  1969-11       Impact factor: 5.330

8.  Regional distribution of calmodulin activity in rat brain.

Authors:  L W Zhou; J A Moyer; E A Muth; B Clark; M Palkovits; B Weiss
Journal:  J Neurochem       Date:  1985-05       Impact factor: 5.372

9.  Benzodiazepine inhibition of the calcium-calmodulin protein kinase system in brain membrane.

Authors:  R J DeLorenzo; S Burdette; J Holderness
Journal:  Science       Date:  1981-07-31       Impact factor: 47.728

10.  Melatonin modifies calmodulin cell levels in MDCK and N1E-115 cell lines and inhibits phosphodiesterase activity in vitro.

Authors:  G Benítez-King; L Huerto-Delgadillo; F Antón-Tay
Journal:  Brain Res       Date:  1991-08-23       Impact factor: 3.252

View more
  1 in total

Review 1.  Voltage-Dependent Calcium Channels, Calcium Binding Proteins, and Their Interaction in the Pathological Process of Epilepsy.

Authors:  Jie-Hua Xu; Feng-Ru Tang
Journal:  Int J Mol Sci       Date:  2018-09-12       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.